Business Context and Reporting Period
This Form 8-K Current Report, dated August 21, 2025, covers corporate governance changes at Silvaco Group, Inc. (SVCO), a Delaware corporation listed on the Nasdaq Global Select Market. The filing details the departure of the Chief Executive Officer and the appointment of a successor.
Key Financial Metrics
The filing does not provide standard financial performance metrics such as revenue, profit, cash flow, margins, debt, or liquidity. The financial data presented is limited to executive compensation and severance arrangements.
- Dr. Taheri Severance: Aggregate cash payments of $975,484 (18 months' base salary plus pro-rata bonus).
- Dr. Taheri Equity: Accelerated vesting of 126,161 unvested restricted stock units.
- Dr. Taheri Benefits: 15 months of COBRA health coverage, 12 months of car lease payments ($12,000), and 2025 life insurance premium ($20,000).
- Dr. Rhines Compensation: Annual base salary of $160,000.
- Dr. Rhines Equity: Eligible for performance-based restricted stock units (PRSUs) with grant-date fair values ranging from $100,000 to $6,252,636, contingent on stock price thresholds.
- Dr. Rhines Severance: Potential lump-sum payment ranging from $500,000 to $1,000,000 depending on tenure, plus accelerated vesting of PRSUs under specific termination conditions.
Material Changes
The primary material change is the leadership transition at the executive level:
- Departure: Dr. Babak A. Taheri stepped down as Chief Executive Officer and Board member, effective August 19, 2025. The departure was mutual and not the result of any disagreement regarding operations or policies.
- Appointment: Dr. Walden C. Rhines was appointed Chief Executive Officer, effective August 19, 2025. Dr. Rhines, age 78, had served as a non-employee Board member since September 2022.
Outlook, Risks, and Management Commentary
Management Commentary: The Board emphasized that the leadership change was a mutual agreement. Dr. Rhines brings extensive experience, having previously served as CEO of Mentor Graphics Corporation (23 years) and Executive Vice President of the Semiconductor Group at Texas Instruments (21 years).
Employment Terms: Dr. Rhines' employment agreement runs from August 19, 2025, to March 31, 2027. His equity compensation is heavily performance-based, tied to the company's trading price levels.
Risks and Contingencies: The filing notes that Dr. Taheri remains bound by restrictive covenants including confidentiality, non-disparagement, and non-solicitation. Dr. Rhines' severance and equity acceleration are contingent upon the execution of a release of claims and compliance with restrictive covenants.
Investor Verification Checklist
- Verify the specific stock price thresholds and volume-weighted average price requirements for Dr. Rhines' PRSU grants.
- Review the full text of the Separation Agreement (Exhibit 10.1) and Employment Agreement (Exhibit 10.2) for detailed clawback provisions or additional conditions.
- Monitor the company's stock price performance relative to the vesting conditions of the new CEO's equity package.
- Confirm the impact of the leadership transition on the company's strategic roadmap, as no operational guidance was provided in this filing.